A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
NCT ID: NCT07268040
Last Updated: 2026-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
400 participants
INTERVENTIONAL
2025-12-23
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
NCT07028281
A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
NCT06605222
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
NCT07229586
A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors
NCT06907628
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
NCT05277168
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SHR-7787 combined with SHR-1316
SHR-7787 injection combined with SHR-1316 injection.
SHR-7787 Injection
SHR-7787 Injection.
SHR-1316 Injection
SHR-1316 Injection.
SHR-7787 combined with SHR-4849
SHR-7787 injection combined with SHR-4849 injection.
SHR-7787 Injection
SHR-7787 Injection.
SHR-4849 Injection
SHR-4849 Injection.
SHR-7787 combined with etoposide and carboplatin/cisplatin
SHR-7787 injection combined with etoposide and carboplatin/cisplatin injection.
SHR-7787 Injection
SHR-7787 Injection.
Etoposide injection
Etoposide Injection.
Carboplatin injection
Carboplatin Injection.
Cisplatin injection
Cisplatin Injection.
SHR-7787 combined with SHR-1316, etoposide, carboplatin/cisplatin
SHR-7787 injection combined with SHR-1316, etoposide, carboplatin/cisplatin injection.
SHR-7787 Injection
SHR-7787 Injection.
SHR-1316 Injection
SHR-1316 Injection.
Etoposide injection
Etoposide Injection.
Carboplatin injection
Carboplatin Injection.
Cisplatin injection
Cisplatin Injection.
SHR-7787 combined with SHR-4849 and SHR-1316
SHR-7787 injection combined with SHR-4849 and SHR-1316 injection.
SHR-7787 Injection
SHR-7787 Injection.
SHR-1316 Injection
SHR-1316 Injection.
SHR-4849 Injection
SHR-4849 Injection.
SHR-7787 combined with SHR-1316 and BP102
SHR-7787 injection combined with SHR-1316 and BP102 injection.
SHR-7787 Injection
SHR-7787 Injection.
SHR-1316 Injection
SHR-1316 Injection.
BP102 Injection
BP102 Injection.
SHR-7787 combined with SHR-4849 and BP102
SHR-7787 injection combined with SHR-4849 and BP102 injection.
SHR-7787 Injection
SHR-7787 Injection.
SHR-4849 Injection
SHR-4849 Injection.
BP102 Injection
BP102 Injection.
SHR-7787 combined with SHR-4849, SHR-1316 and carboplatin/cisplatin
SHR-7787 injection combined with SHR-4849, SHR-1316 and carboplatin/cisplatin injection.
SHR-7787 Injection
SHR-7787 Injection.
SHR-1316 Injection
SHR-1316 Injection.
SHR-4849 Injection
SHR-4849 Injection.
Carboplatin injection
Carboplatin Injection.
Cisplatin injection
Cisplatin Injection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SHR-7787 Injection
SHR-7787 Injection.
SHR-1316 Injection
SHR-1316 Injection.
SHR-4849 Injection
SHR-4849 Injection.
Etoposide injection
Etoposide Injection.
Carboplatin injection
Carboplatin Injection.
Cisplatin injection
Cisplatin Injection.
BP102 Injection
BP102 Injection.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with histologically or cytologically confirmed unresectable solid tumors;
3. At least one measurable lesion was identified per RECIST 1.1;
4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1;
5. Adequate organ functions as defined per protocol;
6. Minimum life expectancy of 3 months.
Exclusion Criteria
2. History of other malignancy within the past 5 years, with exceptions defined in the protocol;
3. Patients with uncontrolled cancer pain;
4. Patients with serious cardiovascular and/or cerebrovascular diseases;
5. Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion;
6. Patients with Severe infections within 4 weeks prior to the first dose;
7. Active pulmonary tuberculosis infection;
8. History of immunodeficiency;
9. History of autoimmune diseases;
10. The adverse events of previous antineoplastic therapy did not recover to CTCAE≤ grade 1;
11. Pregnant or nursing women, or planned to become pregnant during the study period;
12. Known allergic to any component of investigational drugs.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Hengrui Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHR-7787-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.